Get the Weekly Intelligence Brief — top committee picks every Sunday.
ISRG · NASDAQ · STOCK

Intuitive Surgical (ISRG) Stock Analysis

Healthcare Updated August 23, 2026
$378.85
52W $328.57 – $603.88
62/100
$133.83B
42.8
1.46
AI Committee Verdict
Buy
62/100
Conviction: Contested · 50% agreement · 6 analysts
+16.9%
-13.3%
1.27:1
Contested

Is ISRG Bullish or Bearish?

Bullish. Innellis AI committee rates Intuitive Surgical (ISRG) Buy with a composite score of 62/100 , based on 6 analysts with 50% agreement. Last updated August 23, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +13.29 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -6.71 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull & Bear Case

Bull Case
  • ROE of 17.8% shows genuine earnings power backing the valuation — Value
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
  • News sentiment is positive (+0.20 across 46 articles, 14d) — News
Bear Case
  • P/E of 45.2 is expensive by classic value standards — Value
  • Price-to-book of 11.3x prices in significant intangible value — Value
  • Bollinger bandwidth of 18.0% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 23, 2026
Overall Committee Score
62/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 26%
of 192 Healthcare peers
Value Analyst neutral
49 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 17.8% shows genuine earnings power backing the valuation
− P/E of 45.2 is expensive by classic value standards
Growth Analyst bullish
77 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst neutral
58 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 18.0% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
64 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 46 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 61.7 to 61.7.

Comparing 2026-08-22 to 2026-08-23 (1 day apart).

Technical Analysis

RSI (14)
44.3
Neutral
MACD Histogram
1.023
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Lh Ll
Support
$328.62
Resistance
$442.72
Bollinger %B
0.50
Inside Bands
Price vs Moving Averages
EMA 9
$385.92 Below
EMA 21
$383.32 Below
EMA 50
$391.64 Below
EMA 200
$445.72 Below

Fundamental Analysis

Valuation
20
Growth
93
Profitability
95
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio 42.8×
P/B Ratio 7.39×
PEG Ratio 2.02
Dividend Yield 0.00%
52W High $603.88
52W Low $328.57
Quality & Growth
ROE 1602.3%
ROA 1384.3%
Gross Margin 6667.9%
Operating Margin 3127.7%
Revenue Growth YoY
Debt / Equity 0.00
AI Fundamental Assessment
P/E ratio of 42.8 (rich relative to a 15-40x range); Price-to-book of 7.4x; PEG ratio of 2.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 16.0%; Return on assets of 13.8%; Net margin of 28.4%; Gross margin of 66.7%; Current ratio of 4.96 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is positive (9.09); Most recent quarter beat estimates by 9.8%; 5 consecutive earnings beats; EPS growth accelerating (-1.2% -> +12.0% QoQ); Average YoY EPS growth of 27.9%; Analyst estimates rising over recent quarters
Get the Full ISRG Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime